CA2864133A1 - Methods related to treatment of inflammatory diseases and disorders - Google Patents
Methods related to treatment of inflammatory diseases and disorders Download PDFInfo
- Publication number
- CA2864133A1 CA2864133A1 CA2864133A CA2864133A CA2864133A1 CA 2864133 A1 CA2864133 A1 CA 2864133A1 CA 2864133 A CA2864133 A CA 2864133A CA 2864133 A CA2864133 A CA 2864133A CA 2864133 A1 CA2864133 A1 CA 2864133A1
- Authority
- CA
- Canada
- Prior art keywords
- expression
- level
- gene
- inflammatory agent
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention relates to gene markers associated with a method for predicting the clinical response in a patient suffering from an inflammatory diseases or disorders to an anti-inflammatory treatment.
Claims (16)
1. A method for predicting the response of a subject to an anti-inflammatory agent comprising; obtaining information on the level of expression of one or more gene(s) of Figure 1 in a biological sample from said patient, wherein altered expression of one or more of said gene(s) compared to a reference level of said gene(s), is predictive of a response of the subject to the anti-inflammatory agent.
2. A method for predicting the response of a patient to an anti-inflammatory agent comprising a. measuring the level of expression of one or more gene(s) of Figure 1 in a biological sample from said patient and b. comparing said level with a reference level of said gene(s) wherein altered expression of one or more of said gene(s) compared to said reference level, is predictive of a response of the patient to the anti-inflammatory agent.
3. A method for identification of a subject with an increased probability of responding to anti-inflammatory agent comprising; obtaining information on the level of expression of one or more gene(s) of Figure 1 in a biological sample from said subject, wherein altered expression of one or more of said gene(s) compared to a reference level of said gene(s) indicates that a subject with an increased probability of responding to an anti-inflammatory agent has been identified.
4. A method for identification of a patient with an increased probability of responding to anti-inflammatory agent comprising;
a. measuring the level of expression of one or more gene(s) of Figure 1 in a biological sample from said patient b. comparing said level with a reference level of said gene(s), wherein altered expression of one or more of said gene(s) compared to the reference level of said gene(s), indicates that a patient with an increased probability of responding to an anti-inflammatory agent has been identified.
a. measuring the level of expression of one or more gene(s) of Figure 1 in a biological sample from said patient b. comparing said level with a reference level of said gene(s), wherein altered expression of one or more of said gene(s) compared to the reference level of said gene(s), indicates that a patient with an increased probability of responding to an anti-inflammatory agent has been identified.
5. The method according to any of the previous claims, a. wherein the altered expression of a gene of Figure 1A is an increase compared to the reference level and/or b. wherein the altered expression of a gene of Figure 1B is a decrease compared to the reference level.
6. The method according to any of the above claims, wherein the level of expression is measured in a blood sample based on mRNA using PCR, such as multi-plex PCR or qRT-PCR, or micro array chip.
7. The method according to any of the above claims, wherein the level of expression of complement factor D (CFD) is above a reference level.
8. The method according to any of the above claims, a. wherein the level of expression of complement factor D (CFD) is measured by qRT-PCR and wherein the transcript detected with a Cycle Threshold Value (Ct) of 30 using Assay ID: Hs00157263_m1 (Applied Biosystems) or b. wherein the level of expression of complement factor D (CFD) is measured using micro array chip and wherein the level of expression is above 9,5 on a log2 scale of RMA or GC-RMA normalized expression values or c. wherein the level of expression of complement factor D (CFD) is measured by qRT-PCR and wherein the transcript is detected at absolute numbers of at least 0.04 copies of CFD pr. copy of beta-actin mRNA using Assay ID:
Hs00157263_m1 for CFD (Applied Biosystems/ Invitrogen) or d. wherein the level of expression of complement factor D (CFD) is measured indirectly based on one or more CFD expression correlated SNPs.
Hs00157263_m1 for CFD (Applied Biosystems/ Invitrogen) or d. wherein the level of expression of complement factor D (CFD) is measured indirectly based on one or more CFD expression correlated SNPs.
9. A method for treating an inflammatory disease or disorder in a patient comprising administering a therapeutic amount of an anti-inflammatory agent to said patient, wherein, prior to administration of said anti-inflammatory agent, at least one test, according to any of claims 1-8, has shown that the expression levels of one or more of the genes of Figure 1, in a biological sample from said patient is altered compared to a reference level and wherein altered expression level of one or more of said gene(s) compared to a reference level of said gene(s), is predictive of a response of the subject to the anti-inflammatory agent.
10. The method according to any of the above claims, wherein the subject or patient is suffering from an auto-immune disease or disorder, such as Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Multiple Sclerosis (MS), Inflammatory Bowel Disease (IBD), Psoriatic Arthritis (PSA) or psoriasis.
11. The method according to any of the above claims wherein the anti-inflammatory agent is an antagonist of one or more of IL-19, IL-20 and IL-24.
12. The method according to any of the above claims wherein the anti-inflammatory agent is an anti-human IL-20 antibody.
13. An anti-inflammatory agent for treatment of an auto-immune disease or disorder, wherein the patient has an altered expression of one or more of the genes of Figure 1, compared to the reference level of said gene(s).
14. An article of manufacture comprising, packaged together, a pharmaceutical composition comprising an anti-inflammatory agent and a pharmaceutically acceptable carrier and a label stating that the pharmaceutical composition is useful for treating a patient suffering from an auto-immune disease or disorder with an altered expression of one or more of the genes of Figure 1.
15. A kit comprising a. one or more composition comprising at least one detecting agent for determining the expression level of one or more gene(s) from Table 1A and/or Table 1B and b. instructions for use of the kit including how to correlate expression level(s) with response probability of a subject.
16. The kit of claim 15, wherein the detecting agent is for determining expression of complement factor D (CFD).
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12154917 | 2012-02-10 | ||
| EP12154917.4 | 2012-02-10 | ||
| US201261597924P | 2012-02-13 | 2012-02-13 | |
| US61/597,924 | 2012-02-13 | ||
| PCT/EP2013/052629 WO2013117751A2 (en) | 2012-02-10 | 2013-02-11 | Methods related to treatment of inflammatory diseases and disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2864133A1 true CA2864133A1 (en) | 2013-08-15 |
Family
ID=48948117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2864133A Withdrawn CA2864133A1 (en) | 2012-02-10 | 2013-02-11 | Methods related to treatment of inflammatory diseases and disorders |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP2812445A2 (en) |
| KR (1) | KR20140124767A (en) |
| CN (1) | CN104204230A (en) |
| AU (1) | AU2013217940A1 (en) |
| BR (1) | BR112014019274A2 (en) |
| CA (1) | CA2864133A1 (en) |
| MX (1) | MX2014009490A (en) |
| WO (1) | WO2013117751A2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109476698B (en) * | 2016-05-20 | 2023-10-17 | 西达-赛奈医疗中心 | Gene-based diagnosis of inflammatory bowel disease |
| CN110244053B (en) * | 2019-05-09 | 2022-03-11 | 北京大学第三医院（北京大学第三临床医学院） | Molecular marker for diagnosing lupus nephritis and pulmonary hypertension disease and application thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001045261A2 (en) | 1999-12-07 | 2001-06-21 | Parthus Technologies Plc | Model for charge pump phase-locked loop |
| ES2387394T3 (en) | 1999-12-23 | 2012-09-21 | Zymogenetics, Inc. | Inflammation treatment procedure |
| DE10227527A1 (en) | 2002-06-20 | 2004-01-08 | Clariant Gmbh | Process for the preparation of disazo pigments |
| US7435800B2 (en) | 2003-05-23 | 2008-10-14 | Chi-Mei Medical Center | Antibodies to interleukin-20 and method for inhibiting interleukin-20 induced cell proliferation |
| JP4991307B2 (en) | 2003-11-21 | 2012-08-01 | ザイモジェネティクス， インコーポレイテッド | Anti-IL-20 antibodies and binding partners and methods for use in inflammation |
| WO2007006858A2 (en) * | 2005-07-12 | 2007-01-18 | Oy Jurilab Ltd | Method for treatment of cardiovascular and metabolic diseases and detecting the risk of the same |
| IES20050495A2 (en) | 2005-07-20 | 2006-11-01 | Minroc Techn Promotions Ltd | A drill bit assembly for fluid-operated percussion drill tools |
| WO2007038501A2 (en) | 2005-09-27 | 2007-04-05 | The Feinstein Institute For Medical Research | Rheumatoid arthritis markers |
| WO2007081465A2 (en) | 2005-12-09 | 2007-07-19 | Chi-Mei Medical Center | Antibodies to interleukin-20 and method for inhibiting interleukin-20 induced cell proliferation |
| EP1857559A1 (en) | 2006-05-16 | 2007-11-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A method for predicting responsiveness to TNF alpha blocking agents |
| WO2008048986A2 (en) * | 2006-10-17 | 2008-04-24 | Children's Hospital Medical Center | Gene array technique for predicting response in inflammatory bowel diseases |
| JP2010508838A (en) | 2006-11-09 | 2010-03-25 | アンスティテュ ナシオナル ドゥ ラ サントゥ エ ドゥ ラ ルシェルシェ メディカル（イーエヌエスエーエールエム） | Method for predicting therapeutic response to TNF-α blocker |
| WO2008104608A1 (en) | 2007-03-01 | 2008-09-04 | Universite Catholique De Louvain | Method for the determination and the classification of rheumatic conditions |
| WO2008132176A2 (en) | 2007-04-27 | 2008-11-06 | Universite Catholique De Louvain | Method for evaluating the response of an individual to tnf blocking therapy |
| EA017815B1 (en) | 2007-06-08 | 2013-03-29 | Байоджен Айдек Ма Инк. | Biomarkers for predicting anti-tnf responsiveness or non-responsiveness |
| US20090004189A1 (en) * | 2007-06-18 | 2009-01-01 | Genentech, Inc. | Biological markers predictive of rheumatoid arthritis response to b-cell antagonists |
| EP2297203A1 (en) | 2008-06-30 | 2011-03-23 | Novo Nordisk A/S | Anti-human interleukin-20 antibodies |
| WO2010025369A2 (en) | 2008-08-28 | 2010-03-04 | Wyeth | Uses of il-22, il-17, and il-1 family cytokines in autoimmune diseases |
| RU2011140335A (en) | 2009-03-05 | 2013-04-10 | Эбботт Лэборетриз | BINDING IL-17 PROTEINS |
| US20120020954A1 (en) * | 2009-03-30 | 2012-01-26 | Anat Achiron | Methods of predicting clinical course and treating multiple sclerosis |
| EP2473637B1 (en) | 2009-09-03 | 2017-03-29 | F. Hoffmann-La Roche AG | Methods for treating, diagnosing, and monitoring rheumatoid arthritis |
| US8580528B2 (en) * | 2009-10-16 | 2013-11-12 | Stichting Vu-Vumc | Method for prognosticating the clinical response of a patient to B-lymphocyte inhibiting or depleting therapy |
| EP2576824A2 (en) * | 2010-06-07 | 2013-04-10 | Roche Diagnostics GmbH | Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment |
-
2013
- 2013-02-11 KR KR1020147022156A patent/KR20140124767A/en not_active Application Discontinuation
- 2013-02-11 AU AU2013217940A patent/AU2013217940A1/en not_active Withdrawn
- 2013-02-11 CN CN201380019432.0A patent/CN104204230A/en not_active Withdrawn
- 2013-02-11 BR BR112014019274A patent/BR112014019274A2/en not_active IP Right Cessation
- 2013-02-11 WO PCT/EP2013/052629 patent/WO2013117751A2/en active Application Filing
- 2013-02-11 MX MX2014009490A patent/MX2014009490A/en unknown
- 2013-02-11 EP EP13704081.2A patent/EP2812445A2/en not_active Withdrawn
- 2013-02-11 CA CA2864133A patent/CA2864133A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013117751A3 (en) | 2013-10-03 |
| EP2812445A2 (en) | 2014-12-17 |
| CN104204230A (en) | 2014-12-10 |
| MX2014009490A (en) | 2014-08-29 |
| BR112014019274A2 (en) | 2017-06-27 |
| WO2013117751A2 (en) | 2013-08-15 |
| AU2013217940A1 (en) | 2014-07-31 |
| KR20140124767A (en) | 2014-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Christmann et al. | miR-155 in the progression of lung fibrosis in systemic sclerosis | |
| Raheja et al. | Correlating serum micrornas and clinical parameters in amyotrophic lateral sclerosis | |
| Meng et al. | Identification of latent tuberculosis infection-related microRNAs in human U937 macrophages expressing Mycobacterium tuberculosis Hsp16. 3 | |
| EP2559772B1 (en) | Methods for determining a hepatocellular carcinoma subtype | |
| JP5727484B2 (en) | Type I interferon diagnostics | |
| Kottyan et al. | Genetics of eosinophilic esophagitis | |
| Cao et al. | Role of MiRNAs in inflammatory bowel disease | |
| Zheng et al. | Differential microRNA expression in human macrophages with Mycobacterium tuberculosis infection of Beijing/W and non-Beijing/W strain types | |
| Wu et al. | The epigenetics of lupus erythematosus | |
| Cai et al. | STAT3-dependent transactivation of miRNA genes following Toxoplasma gondii infection in macrophage | |
| JP2016507233A5 (en) | ||
| Shi et al. | MicroRNA-219a-5p suppresses intestinal inflammation through inhibiting Th1/Th17-mediated immune responses in inflammatory bowel disease | |
| Alacam et al. | miR-181b-5p, miR-195-5p and miR-301a-3p are related with treatment resistance in schizophrenia | |
| Wang et al. | Emerging insights into the role of epigenetics and gut microbiome in the pathogenesis of Graves’ ophthalmopathy | |
| Barzago et al. | A novel infection-and inflammation-associated molecular signature in peripheral blood of myasthenia gravis patients | |
| Nordor et al. | The early pregnancy placenta foreshadows DNA methylation alterations of solid tumors | |
| JP2011509071A5 (en) | ||
| JP2012533322A5 (en) | ||
| Guo et al. | Epigenetics in the treatment of systemic lupus erythematosus: potential clinical application | |
| JP2022512796A (en) | Type I interferon signature and usage | |
| Yamamoto-Furusho et al. | Protective role of Interleukin 27 (IL-27) gene polymorphisms in patients with ulcerative colitis | |
| JP2017532961A (en) | Methods and compositions for treating subjects with SMAD7 antisense oligonucleotides | |
| Kõks et al. | Psoriasis-specific RNA isoforms identified by RNA-seq analysis of 173,446 transcripts | |
| Wu et al. | LncRNA NEAT1 promotes gastric cancer progression via miR-1294/AKT1 axis | |
| EP3510167B1 (en) | Methods and compositions for predicting chronic lung allograft dysfunction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AZWI | Withdrawn application |
Effective date: 20141219 |
|
| AZWI | Withdrawn application |
Effective date: 20141219 |